Editas Medicine is a transformative genome editing company which is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. The Company operates through developing and commercializing genome editing technology segment. Editas Medicine is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats technology.
Type
Public
HQ
Cambridge, US
Founded
2013
Size (employees)
89 (est)
Editas Medicine was founded in 2013 and is headquartered in Cambridge, US
Report incorrect company information

Key People/Management at Editas Medicine

Katrine Bosley

Katrine Bosley

CEO
Andrew Hack

Andrew Hack

CFO
Gerald Cox

Gerald Cox

Chief Medical Officer
Charles Albright

Charles Albright

Chief Scientific Officer
Keith Joung

Keith Joung

Co - Founder

Editas Medicine Office Locations

Editas Medicine has an office in Cambridge
Cambridge, US (HQ)
11 Hurley St
Show all (1)
Report incorrect company information

Editas Medicine Financials and Metrics

Editas Medicine Financials

USD

Net income (Q2, 2017)

(26.4 m)

EBIT (Q2, 2017)

(26.1 m)

Market capitalization (20-Apr-2018)

1.4 b

Cash (30-Jun-2017)

144.1 m

EV

1.3 b
Editas Medicine's current market capitalization is $1.4 b.
Annual
USDFY, 2016

General and administrative expense

46.3 m

R&D expense

57 m

Operating expense total

103.2 m

EBIT

(97.2 m)
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

General and administrative expense

9.8 m12.2 m11.3 m12.3 m11.9 m

R&D expense

8.9 m10.4 m10.8 m19 m17.3 m

Operating expense total

18.6 m22.6 m22.1 m31.3 m29.2 m

EBIT

(17.8 m)(19.2 m)(21.2 m)(30.6 m)(26.1 m)
Annual
USDFY, 2016

Cash

185.3 m

Accounts Receivable

88 k

Inventories

1.8 m

Current Assets

187.2 m
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Cash

229.2 m217.7 m199.9 m351.6 m144.1 m

Accounts Receivable

1.1 m1.2 m1.1 m945 k820 k

Current Assets

232.2 m221.2 m203.4 m353.8 m327.9 m

PP&E

15 m26.7 m37.1 m39.6 m39.4 m
Annual
USDFY, 2016

Net Income

(97.2 m)

Inventories

1.8 m

Accounts Payable

4.6 m
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(17.7 m)(19 m)(21 m)(31.1 m)

Accounts Payable

2.9 m5.8 m3.7 m15.2 m
USDY, 2017

EV/EBIT

-48.9 x

Financial Leverage

2 x
Show all financial metrics

Editas Medicine Operating Metrics

FY, 2016

Patents Issued

41

Patents Pending

500
Show all operating metrics
Report incorrect company information